Bulletin from Egetis Therapeutics’ Annual General Meeting 2024

May 6, 2024

Stockholm, Sweden, May 6, 2024. Egetis Therapeutics AB (publ) (STO: EGTX) today announced that the Annual General Meeting (AGM) has been held on May 6, 2024, at which the submitted proposals were passed. The complete proposals are stated in the notice to the Annual General Meeting.

The Annual General Meeting was held by physical presence of shareholders and with the option for shareholders to exercise their voting rights by advance voting (postal voting). Among other items of business, the following resolutions were taken:

The income statements and balance sheets were adopted, together with the Board of Directors' proposal for allocation of the company’s result. The Board of Directors and CEO were discharged from liability for the financial year 2023.

Thomas Lönngren, Mats Blom, Gunilla Osswald, Behshad Sheldon, Elisabeth Svanberg and Peder Walberg were re-elected as members of the Board of Directors. Mats Blom was elected as new Chairman of the Board of Directors.

The Annual General Meeting voted on the Board of Directors’ fees in accordance with the Nomination Committee’s proposal as follows:

It was resolved that remuneration shall be paid with SEK 630,000 for the Chairman of the Board of Directors, SEK 235,000 for other board members not employed by the company and that no remuneration be paid to Board members who are employed by the company. Furthermore, SEK 80,000 shall be paid to the Chairman of the Audit Committee and SEK 40,000 to each other member of the Audit Committee. Furthermore, SEK 50,000 shall be paid to the Chairman of the Remuneration Committee and SEK 25,000 to each other member of the Remuneration Committee. Finally, SEK 80,000 shall be paid to the Chairman of the Market Access Committee and SEK 40,000 to each other member of the Market Access Committee.

It was resolved to elect the registered accounting firm Öhrlings PricewaterhouseCoopers AB (PwC) as auditor. Authorized public accountant Niclas Bergenmo will assume the role as auditor in charge.

The Nomination Committee´s proposal regarding the establishment of a Nomination Committee and Nomination Committee instructions was approved.

The Annual General Meeting approved the Board of Directors’ remuneration report for 2023.

The Annual General Meeting resolved to amend the articles of association whereby the limits for the share capital and the number of shares are increased in order to enable the registration of a greater number of shares, a new class of shares (class C shares) is introduced to enable issues of class C shares under the company’s long-term incentive programs, and that a new paragraph is introduced which authorizes the Board of Directors to resolve that persons not being shareholders shall be allowed to attend general meetings.

The Annual General Meeting approved the Board of Directors’ proposal regarding the introduction of a long-term incentive program for the company’s management and key personnel and amendments of the terms and conditions of the currently outstanding long-term incentive programs adopted in 2021, 2022 and 2023.

The Annual General Meeting voted, in accordance with the Board of Directors’ proposal, to authorize the Board of Directors to issue shares, convertibles and/or warrants.

Minutes with complete resolutions from the Annual General Meeting will be made available on the company´s website, www.egetis.com.

About Egetis Therapeutics

Egetis Therapeutics is an innovative and integrated pharmaceutical company, focusing on projects in late-stage development for commercialization for treatments of serious diseases with significant unmet medical needs in the orphan drug segment.

The Company’s lead drug candidate Emcitate® (tiratricol) is under development for the treatment of patients with monocarboxylate transporter 8 (MCT8) deficiency, a highly debilitating rare disease with no available treatment. In previous studies (Triac Trial I and a long-term real-life study) Emcitate has shown highly significant and clinically relevant results on serum thyroid hormone T3 levels and secondary clinical endpoints. Egetis submitted a marketing authorisation application (MAA) for Emcitate to the European Medicines Agency (EMA) in October 2023.

After a dialogue with the FDA, Egetis is conducting a randomized, placebo-controlled pivotal study in 16 evaluable patients to verify the results on T3 levels seen in previous clinical trials and publications. Egetis will update the market as soon as recruitment has been completed and at that point inform about the timing of availability of top-line results, and the expected timing of the subsequent NDA filing.

Emcitate holds Orphan Drug Designation (ODD) for MCT8 deficiency and resistance to thyroid hormone type beta (RTH-beta) in the US and the EU. MCT8 deficiency and RTH-beta are two distinct indications, with no overlap in patient populations. Emcitate has been granted Rare Pediatric Disease Designation (RPDD) which gives Egetis the opportunity to receive a Priority Review Voucher (PRV) in the US, after approval. This voucher can be transferred or sold to another sponsor.

The drug candidate Aladote® (calmangafodipir) is a first in class drug candidate developed to reduce the risk of acute liver injury associated with paracetamol (acetaminophen) overdose. A proof of principle study has been successfully completed. The design of a pivotal Phase IIb/III study (Albatross), with the purpose of applying for market approval in the US and Europe, has been finalized following interactions with the FDA, EMA and MHRA. The study start has been postponed until Emcitate marketing authorization submissions for MCT8 deficiency have been completed. Aladote has been granted ODD in the US and in the EU.

Egetis Therapeutics (STO: EGTX) is listed on the Nasdaq Stockholm main market. For more information, see www.egetis.com

Bulletin from Egetis Therapeutics’ Annual General Meeting 2024

Contact us